KRAS and lung adenocarcinoma: Mutation or loss of STK11 is associated with low or absent PD-L1 expression, in both KRAS-mutant and KRAS-wild type lung adenocarcinoma, and with impaired efficacy of ICIs targeting the PD-1/PD-L1 axis [16,54].